I read with interest the expert consensus by Meyer et al.1 regarding strategic priorities in lung cancer. While it provides a vital synthesis, the current roadmap faces significant methodological and clinical dilemmas that warrant discussion.
I read with interest the expert consensus by Meyer et al.1 regarding strategic priorities in lung cancer. While it provides a vital synthesis, the current roadmap faces significant methodological and clinical dilemmas that warrant discussion.